Your search for inflammatory bowel disease returned 233 results

Vedolizumab is currently available for administration as an IV infusion under the brand name Entyvio.

Benefit for incident CRC was duration-dependent, with significantly reduced risk after two or more years of use

Findings seen for Crohn disease, but not ulcerative colitis.

A 40-year-old woman presents to the clinic with multiple red-brown and violaceous nodules along the extensor surface of her fingers that have recurred over the past 3 years.

Researchers examined whether the conventional measure of screening CRC is accurate in determining screening status in patients younger or older than the standard age range.

Researchers examined health outcomes of short- and long-term treatment with opioids among patients with inflammatory bowel disease.

A total of 70,177,200 individuals were included in the final analysis; 234,840 had CRC and 69,942,360 had no CRC.

Researchers investigated whether chronic tophaceous gout would increase risk for colorectal cancer.

Results showed that 20.3% of patients treated with risankizumab achieved clinical remission at week 12 compared with 6.2% of patients who received placebo.

Researchers examined risk for herpes zoster infection with biologics and small molecules for IBD.